This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
At week 12 in a clinical trial, Premarin Vaginal Cream was clinically proven to make moderate to severe painful sex due to menopause more comfortable at just 0.5 g twice weekly1
P<.001 Premarin Vaginal Cream vs placebo.
†Severity score: 1=mild, 2=moderate, 3=severe.2
P<.001 Premarin Vaginal Cream vs placebo.
Placebo cream 0.5 g twice weekly (n=68) increased superficial cells from 0.5% to 2.0% and decreased parabasal cells from 63.9% to 54.8% after 12 weeks of treatment.2
| Premarin Vaginal Cream is proven to help rebuild vaginal tissue to near premenopausal levels2,3§ |
Placebo cream 0.5 g twice weekly (n=64) reduced vaginal pH from 6.7 at baseline to 6.4 at week 12.2
P<.001 Premarin Vaginal Cream vs placebo.
No conclusions can be made regarding significance or the individual components comprising
the total composite score.
‡Genital Health Clinical Evaluation is a tool used to measure overall vaginal health by using a total composite score of the parameters listed above. Individual components were not analyzed separately.
Results from a 12-week, randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of Premarin Vaginal Cream in generally healthy postmenopausal women aged 44 to 77 years (N=423), who at baseline had ≤5% superficial cells on a vaginal smear, a vaginal pH ≥5.0, and who identified a most bothersome moderate to severe symptom of vulvar and vaginal atrophy. Premarin Vaginal Cream was administered using 2 dosing regimens: 0.5 g twice weekly and 0.5 g once daily (21 days on/7 days off). The study consisted of an initial 12-week trial followed by an open-label extension to assess endometrial safety through week 52.
Primary end points were the changes from baseline in Vaginal Maturation Index, vaginal pH, and severity of patient-reported most bothersome symptom at week 12. Participants defined the severity of their most bothersome symptom on the following scale: 1=mild, 2=moderate, 3=severe. For most women, dyspareunia was identified as the most bothersome symptom at baseline. Weekly severity score is an average of the daily scores.1,2
Premarin Vaginal Cream. Prescribing information. Pfizer; 2024.
Start your appropriate patients with samples
With Pfizer’s MHT Rx savings card, eligible patients may pay as little as $25*
Learn More
Click here for Full Terms and Conditions
*Eligibility required. No Membership Fees. This is not health insurance. Available to commercially insured patients only. State and federal beneficiaries and cash-paying patients not eligible. Savings up to $250 per prescription fill. Maximum benefit per patient is $1,440 per calendar year. Terms and Conditions apply.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2025 Pfizer Inc. All rights reserved.
Premarin® (conjugated estrogens) Vaginal Cream is indicated for the treatment of atrophic vaginitis and kraurosis vulvae; and for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia.
The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women with daily oral conjugated estrogens (CE) 0.625mg alone relative to placebo. The WHI estrogen plus progestin substudy reported increased risks of DVT, pulmonary embolism, stroke, and myocardial infarction in postmenopausal women with daily oral CE 0.625mg combined with medroxyprogesterone acetate (MPA) 2.5mg relative to placebo.
The WHI Memory Study (WHIMS) reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older, in both the estrogen alone and estrogen plus progestin arms. It is unknown whether these findings apply to younger postmenopausal women.
The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer.
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE or CE and MPA, and other dosage forms of estrogen or combinations and dosage forms of estrogens and progestins.
Estrogens with or without progestins should be prescribed at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman.
Premarin Vaginal Cream should not be used in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or a history of breast cancer; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism, or a history of these conditions; active arterial thromboembolic disease (e.g., stroke, myocardial infarction), or a history of these conditions; anaphylactic reaction or angioedema with Premarin Vaginal Cream; liver dysfunction or disease; thrombophilic disorders; pregnancy.
Consistent with the WHI clinical trials, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. One large meta-analysis of prospective cohort studies reported increased risks that were dependent upon duration of use and could last up to >10 years after discontinuation of estrogen plus progestin therapy and estrogen‑alone therapy. Extension of the WHI trials also demonstrated increased breast cancer risk associated with estrogen plus progestin therapy.
The WHI estrogen plus progestin sub-study reported a statistically non-significant increased risk of ovarian cancer. A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown.
Estrogens increase the risk of gallbladder disease. Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or cholestatic jaundice occurs. Monitor thyroid function in women on thyroid replacement therapy, because estrogens may be associated with increased thyroid binding globulin (TBG) levels.
The most common adverse reactions (≥2%) were headache, pelvic pain, vasodilation, breast pain, leucorrhea, metrorrhagia, vaginitis, and vulvovaginal disorder.
Premarin Vaginal Cream is indicated for the treatment of atrophic vaginitis and kraurosis vulvae; and for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
Please see full Prescribing Information, including BOXED WARNING and Patient Information.
In a prespecified secondary endpoint,
Overall vaginal health was assessed at baseline and week 122
Overall vaginal health was a total composite score of:
No conclusions can be made regarding significance or the individual components comprising the total composite score.
‡Genital Health Clinical Evaluation is a tool used to measure overall vaginal health by using a total composite score of the parameters listed above. Individual components were not analyzed separately.
Please make a selection from the Samples and/or Savings Card(s) available to you.